December 2025

Excerpt:
The FDA has granted approval to Novartis for Itvisma (onasemnogene abeparvovec-brve), the first gene replacement therapy for spinal muscular atrophy (SMA) available for patients aged 2 years and older. Backed by data from the Phase 3 STEER and Phase 3b STRENGTH trials, this one-time intrathecal treatment addresses the genetic root cause of SMA and is expected to be available in the U.S. this December.

Excerpt : Despite advances in technology, cardiovascular death rates remain stagnant. Interventional cardiologist Dr. Koushik Reddy argues for a radical paradigm shift—moving the foundation of care from the cath lab to the “kitchen table.” Learn how he uses the “CARROTS” framework to integrate lifestyle medicine into critical cardiac care.

Persistent maternal thyroid dysfunction—especially when it spans multiple trimesters—significantly increases the risk of autism in children. A 2.68-fold rise in autism diagnoses was observed in cases where thyroid imbalance occurred both before and during pregnancy, underscoring the need for careful monitoring and timely treatment adjustments.